---
title: "Understanding the Market | RemeGen's stock rises over 5% as revenue in the first three quarters increases by 40% year-on-year, with losses significantly narrowing"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263642534.md"
description: "RemeGen rose over 5%, as of the time of writing, up 5.44%, reported at HKD 89.1, with a transaction volume of HKD 225 million. In terms of news, RemeGen announced its performance for the first three quarters of 2025, with operating revenue of approximately RMB 1.72 billion, a year-on-year increase of 42.27%; the net loss attributable to shareholders of the listed company was approximately RMB 551 million, a year-on-year narrowing of 48.6%. The company indicated that due to a significant increase in product sales revenue, along with the optimization of its R&D pipeline and a decrease in various R&D expenses, coupled with the licensing agreement with the U.S. company Vor Bio to grant a paid license for the independently owned intellectual property of TaiTasiPu, this led to a reduction in overseas clinical costs for TaiTasiPu, resulting in a significant decrease in losses for the year. Additionally, on a quarterly basis, the company's third-quarter operating revenue was RMB 622 million, a year-on-year increase of 33.13%; the loss attributable to shareholders was RMB 101 million"
datetime: "2025-10-31T02:16:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263642534.md)
  - [en](https://longbridge.com/en/news/263642534.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263642534.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/263642534.md) | [繁體中文](https://longbridge.com/zh-HK/news/263642534.md)


# Understanding the Market | RemeGen's stock rises over 5% as revenue in the first three quarters increases by 40% year-on-year, with losses significantly narrowing

According to Zhitong Finance APP, RemeGen (09995) rose over 5%, with a current increase of 5.44%, priced at HKD 89.1, and a transaction volume of HKD 225 million.

In terms of news, RemeGen announced its performance for the first three quarters of 2025, with operating revenue of approximately RMB 1.72 billion, a year-on-year increase of 42.27%; the net loss attributable to shareholders of the listed company was approximately RMB 551 million, narrowing by 48.6% year-on-year. The company indicated that due to a significant increase in product sales revenue, along with the optimization of its R&D pipeline and a decrease in various R&D expenses, as well as the licensing agreement with the U.S. company Vor Bio for the paid licensing of the independently owned intellectual property TaiTasiPu, the overseas clinical costs for TaiTasiPu were reduced, leading to a significant decrease in losses this year. Additionally, on a quarterly basis, the company's operating revenue for the third quarter was RMB 622 million, a year-on-year increase of 33.13%; the loss attributable to shareholders was RMB 101 million

### 相关股票

- [RemeGen (688331.CN)](https://longbridge.com/zh-CN/quote/688331.CN.md)
- [REMEGEN (09995.HK)](https://longbridge.com/zh-CN/quote/09995.HK.md)

## 相关资讯与研究

- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-CN/news/281458440.md)
- [Jeffries: ‘What Trump has done is decimate the bank accounts of the American people’](https://longbridge.com/zh-CN/news/281653262.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-CN/news/281644038.md)
- [The Memo: Bondi’s failure to get Trump his ‘scalps’ sealed her fate](https://longbridge.com/zh-CN/news/281627173.md)
- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-CN/news/281035304.md)